Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant pseudomonas aeruginosa
Cargando...
Archivos
Fecha
Título de la revista
Publicado en
Clinical Infectious Diseases, 1537-6591, Vol. 65, Nro. 1, 2017, p. 158–161
Publicado por
Oxford University Press
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
Palabras clave
Keywords
Ceftolozane, Carbapenem resistant, P. aeruginosa, Multidrug resistant